Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05415293
Other study ID # Mozurkewich 10-417
Secondary ID UL1RR031977
Status Terminated
Phase N/A
First received
Last updated
Start date May 2011
Est. completion date May 2011

Study information

Verified date January 2024
Source University of New Mexico
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare blood levels of women who take commericially available, low dose docosahexaenoic acid (DHA) dietary supplements in pregnancy with women who do not take supplements.


Description:

The investigators recruited 73 pregnant women in the late third trimester from a low-risk midwifery clinic in compliance with the protocol approved by the investigators institutional review board regulations (HRPO #10-417). All women in the clinic were offered participation and enrollment was performed at 34-36 weeks gestational age for those who agreed. Exclusion criteria included, preeclampsia, gestational diabetes or pre-gestational diabetes, chronic use of medications, and other medical complication of pregnancy. Maternal data including age, gravidity, parity, gestational age, ethnicity, BMI at delivery, and mode of delivery were collected in compliance with the Health Insurance Portability and Accountability Act guidelines. Neonatal data, including gender, birth weight, height, and head circumference and maternal delivery charactersitics were collected after reviewing the delivery record. Subjects consented to randomization into a group receiving a fish oil based 275mg Promise DHA (Biotegrity; Granbury, TX) by mouth each day, or an algae-based 200mg Expecta DHA (Mead Johnson; Evansville, IN) by mouth each day, or dietary habits as usual. Randomization assignments were concealed in opaque envelopes and revealed at the time of enrollment. Calendars were kept to document supplement use and unused supplements were turned in at the time of admission to labor and delivery. Pill counts were performed to verify the accuracy of calendars. Sample size considerations: The investigators primary outcome measure was DHA level in maternal serum and neonatal cord blood. To detect a 15% increase in DHA proportions, it would require a sample size of 19 in each group. This study is a pilot investigation, designed to determine if a larger supplementation study would be feasible in the investigators population. Collection of blood samples A venous blood sample was collected from each participant at the time of enrollment and randomization. Maternal blood was drawn from the antecubital fossa in tubes containing EDTA and stored at -4 degrees C. A second maternal sample was retrieved at the time of admission for labor in a similar fashion. Neonatal samples were similarly collected at the time of delivery, just after cord clamping. Within 72 hours of collection, nonhemolyzed maternal and neonatal samples were identified and centrifuged for 5 minutes in a clinical centrifuge, and the plasma portion was extracted and stored in 2-mL vials at -78 degrees C until fatty acid analysis was performed. Fatty acid analyses: Samples were allowed to thaw at room temperature and lipid extraction was performed using chloroform/methanol (2:1, v/v) according to the method of Folch et al (1957). The extracted lipid residue was weighed after drying at 45oC under a stream of nitrogen. The total phospholipid component of serum was isolated by silicic acid column chromatography (26) of the total lipid fraction obtained by extracting a 1-mL aliquot of serum with chloroform: methanol (2:1,v/v). Fatty acids were transesterified to generate methyl esters using 0.5 N NaOH in methanol and 14% (w/v) boron trifluoride in methanol (27). Undecenoic acid (Nu-Check Prep, Elysian, MN) was added prior to methylation, and served as an internal standard. Fatty acid methyl esters were quantified using a gas chromatograph (6890N, Agilent Technologies, Sunnyvale, CA) equipped with an autoinjector, a split/splitless capillary injection system, and a flame ionization detector as described elsewhere(28)(). A customized fatty acid mixture described by Loor and Herbein (28) and made with pure methyl ester standards, including AA and DHA, (Nu-Check Prep, Elysian, MN, USA; Sigma, St. Louis, MO, USA) was used to identify peaks and determine response factors for integration with a Chem DataStation (Agilent Technologies, Sunnyvale, CA).


Recruitment information / eligibility

Status Terminated
Enrollment 72
Est. completion date May 2011
Est. primary completion date May 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Pregnant 2. 34-36 weeks gestational age Exclusion Criteria: 1. Maternal medical disease 2. Gestational diabetes 3. Pre-eclampsia 4. Fetal anomalies 5. Ingestion of DHA or fish oil dietary supplements during the current pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Expecta 200mg DHA

Promise 275mg DHA


Locations

Country Name City State
United States University of New Mexico Hospital Albuquerque New Mexico

Sponsors (2)

Lead Sponsor Collaborator
University of New Mexico National Center for Research Resources (NCRR)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Wolfe MD, Chuang LT, Rayburn WF, Wen PC, VanderJagt DJ, Glew RH. Low fatty acid concentrations in neonatal cord serum correlate with maternal serum. J Matern Fetal Neonatal Med. 2012 Aug;25(8):1292-6. doi: 10.3109/14767058.2011.631064. Epub 2012 Apr 24. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Maternal serum DHA weight % at delivery Weight proportion of DHA in the total plasma phospholipids after supplementation 5 months
Primary DHA in newborn cord blood after supplementation Weight proportion of DHA in the total plasma phospholipids of newborn cord blood after maternal supplementation up to 72 hours
See also
  Status Clinical Trial Phase
Completed NCT03442582 - Afluria Pregnancy Registry
Terminated NCT02161861 - Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study N/A
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04548102 - Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman N/A
Completed NCT03218956 - Protein Requirement During Lactation N/A
Completed NCT02191605 - Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy N/A
Completed NCT02223637 - Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
Recruiting NCT06049953 - Maternal And Infant Antipsychotic Study
Completed NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Not yet recruiting NCT06336434 - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy Phase 1/Phase 2
Not yet recruiting NCT04786587 - Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
Not yet recruiting NCT05412238 - Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months N/A
Not yet recruiting NCT05028387 - Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
Completed NCT02783170 - Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women Phase 4
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Recruiting NCT02564250 - Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women N/A
Recruiting NCT02619188 - Nutritional Markers in Normal and Hyperemesis Pregnancies N/A
Completed NCT02520687 - Effects of Dietary Nitrate in Hypertensive Pregnant Women Phase 1